Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests

Heather Gelhorn (), Melissa M. Ross, Anuraag R. Kansal, Eric T. Fung, Michael V. Seiden, Nicolas Krucien and Karen C. Chung
Additional contact information
Heather Gelhorn: Evidera, Inc.
Melissa M. Ross: Evidera, Inc.
Anuraag R. Kansal: GRAIL LLC, a subsidiary of Illumina Inc. (currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October, 2021)
Eric T. Fung: GRAIL LLC, a subsidiary of Illumina Inc. (currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October, 2021)
Michael V. Seiden: McKesson
Nicolas Krucien: Evidera, Inc.
Karen C. Chung: GRAIL LLC, a subsidiary of Illumina Inc. (currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October, 2021)

The Patient: Patient-Centered Outcomes Research, 2023, vol. 16, issue 1, No 6, 43-56

Abstract: Abstract Background Emerging blood-based multi-cancer early detection (MCED) tests can detect a variety of cancer types across stages with a range of sensitivity, specificity, and ability to predict the origin of the cancer signal. However, little is known about the general US population’s preferences for MCED tests. Objective To quantify preferences for MCED tests among US adults aged 50–80 years using a discrete choice experiment (DCE). Methods To quantify preferences for attributes of blood-based MCED tests, an online DCE was conducted with five attributes (true positives, false negatives, false positives, likelihood of the cancer type unknown, number of cancer types detected), among the US population aged 50–80 years recruited via online panels and social media. Data were analyzed using latent class multinomial logit models and relative attribute importance was obtained. Results Participants (N = 1700) were 54% female, mean age 63.3 years. Latent class modeling identified three classes with distinct preferences for MCED tests. The rank order of attribute importance based on relative attribute importance varied by latent class, but across all latent classes, participants preferred higher accuracy (fewer false negatives and false positives, more true positives) and screenings that detected more cancer types and had a lower likelihood of cancer type unknown. Overall, 72% of participants preferred to receive an MCED test in addition to currently recommended cancer screenings. Conclusions While there is significant heterogeneity in cancer screening preferences, the majority of participants preferred MCED screening and the accuracy of these tests is important. While the majority of participants preferred adding an MCED test to complement current cancer screenings, the latent class analyses identified a small (16%) and specific subset of individuals who value attributes differently, with particular concern regarding false-negative and false-positive test results, who are significantly less likely to opt-in.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40271-022-00589-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:16:y:2023:i:1:d:10.1007_s40271-022-00589-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-022-00589-5

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().